A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 18, 2023
End Date
October 30, 2028
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 18, 2023
End Date
October 30, 2028